Clinical trial NCT00747526: A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive
Official title: A Pharmacokinetic, Pharmacodynamic and Safety Study of Single and Multiple Doses of Rabeprazole in Pediatric Subjects With GERD 1 to 11 Months Old, Inclusive
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Gastroesophageal Reflux Disease (GERD)
Keywords: Gastroesophageal Reflux Disease (GERD)
Pediatrics
Pharmacokinetics
Pharmacodynamics
Rabeprazole
GERD
Aciphex
Lead sponsor: Janssen Research & Development, LLC
Sponsor class: INDUSTRY
Collaborators: name: Eisai Inc.
First posted: 2008-09-05
Enrollment: 51
Sex: ALL
Minimum age (years): 1
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate the pharmacokinetics (how the drug is absorbed in the body, how it is distributed within the body and removed from the body over time), pharmacodynamics (how the study medication affects the body) and safety of rabeprazole after single and multiple daily administration in infants between the ages of 1 and 11 months, inclusive, with Gastroesophageal Reflux Disease (GERD).

Detailed description: This is an open-label (both physician and patient know the name of the study medication), multicenter, Phase I study, consisting of 2 parts. The first part of the study will be nonrandomized (study drug is intentionally assigned), and all patients will receive the same dose. In the second part of the study, patients will be randomized (study medication assigned by chance) into 2 dose groups. The purpose of the study is to evaluate the pharmacokinetics (PK), pharmacodynamics (intraesophageal/intragastric pH, clinical global impression, formulation palatability and Gastroesophageal Reflux Disease (GERD) daily symptom diary) and safety of rabeprazole after single and multiple daily administration at 2 dose levels in children between the ages of 1 and 11 months, inclusive (up to 11 months 29 days), with GERD. As this study is an exploratory assessment of the PK, pharmacodynamics and safety of rabeprazole in children, no formal hypothesis testing is applied. Safety and tolerability, including monitoring of adverse events, clinical laboratory results, physical examination, vital signs and electrocardiogram measurements (the measuring of the electrical currents in the heart), will be evaluated throughout the study. Patients will receive rabeprazole sodium as single daily oral doses for 5 successive days (Option 1), or up to 14 successive days (10 days minimum) (Option 2) as a bead formulation. In Part 1, patients will receive single and multiple daily (every 24 hours) doses of 0.5 mg/kg, using increments of 1 mg dose. Safety and PK data from Part 1 of the study will determine the 2 dosages to be studied in Part 2 of the study. In Part 2, patients may receive rabeprazole sodium as single daily oral doses for up to a maximum of 28 consecutive days as a bead formulation. Patients will be randomized into either the 5 mg dose or 10 mg dose group.

Eligibility criteria: Inclusion Criteria:

* Minimum weight of 5 kg (treatment Option 1) or 3 kg (treatment Option 2) with a diagnosis of GERD
* Informed consent signed by at least one parent
* Patients who have been treated with, or are currently receiving a proton pump inhibitor (PPI), H2 blockers, or antacids are eligible (as long as they can go off antacids for 24 hours, and PPIs and H2 blockers for three days prior to dosing, except for cimetidine, which must be discontinued for at least seven days prior to dosing) and remain off these medications for the treatment period

Exclusion Criteria:

* Patients who have history of or current clinically significant medical illness (excluding GERD) including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, infection, or any other illness that the investigator considers should exclude the patient or that could interfere with the interpretation of the study results
* Primary pulmonary or ears, nose, and throat (ENT) symptoms
* History of or current presence of peptic ulcers
* Presence of "warning signals", suggesting cause of vomiting/regurgitation other than GERD
* Any condition which would make the patient, in the opinion of the Investigator or Sponsor, unsuitable for the study

Primary outcomes:
measure: Pharmacokinetic parameters
timeFrame: At Days 1, 5, and 10
measure: Pharmacodynamic parameters
timeFrame: At Days 1, 5, and 10
Secondary outcomes:
measure: Number of Patients with Adverse Events as a Measure of Safety
timeFrame: Approximately 9 weeks
Other outcomes:
Locations:
city: Little Rock
country: United States
state: Arkansas
city: Oakland
country: United States
state: California
city: Washington
country: United States
state: District of Columbia
city: Maitland
country: United States
state: Florida
city: Louisville
country: United States
state: Kentucky
city: Jackson
country: United States
state: Mississippi
city: Bridgeton
country: United States
state: Missouri
city: Long Branch
country: United States
state: New Jersey
city: Greenville
country: United States
state: North Carolina
city: Cleveland
country: United States
state: Ohio
city: Toledo
country: United States
state: Ohio
city: Youngstown
country: United States
state: Ohio
city: Houston
country: United States
state: Texas
city: Antwerpen
country: Belgium
city: Brussel
country: Belgium
city: Sao Paulo
country: Brazil
city: Lublin
country: Poland
city: Warszawa
country: Poland
city: Barnsley N/A
country: United Kingdom
city: London
country: United Kingdom
Study officials:
affiliation: Janssen Research & Development, LLC
name: Janssen Research & Development, LLC Development, L.L.C. Clinical Trial
role: STUDY_DIRECTOR
References:
citation: Treem W, Hu P, Sloan S. Normal and proton pump inhibitor-mediated gastrin levels in infants 1 to 11 months old. J Pediatr Gastroenterol Nutr. 2013 Oct;57(4):520-6. doi: 10.1097/MPG.0b013e31829b6914.